Harmony Biosciences is trading 5.4% down in pre-market at $38.30, with the decline appearing aligned with broader risk-off conditions, including weaker U.S. equity futures and elevated Treasury yields. - It closed at $40.48 on September 23, 2026. - No clear company-specific announcement, earnings release, regulatory action, or analyst change was identified for September 24. - Acquisition discussions reported on September 23 were not presented as a cause of the pre-market decline.